A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient

Transpl Infect Dis. 2007 Mar;9(1):51-4. doi: 10.1111/j.1399-3062.2006.00159.x.

Abstract

Acanthamoeba species are known to cause 2 well-described entities: (1) granulomatous amoebic encephalitis (GAE), which usually affects immunocompromised hosts, and (2) keratitis, which typically follows trauma associated with contamination of water or contact lenses. Less common manifestations include pneumonitis and a subacute granulomatous dermatitis. We describe a case of granulomatous dermatitis secondary to Acanthamoeba infection in a lung transplant recipient and a successful outcome following treatment with lipid formulation of amphotericin B and voriconazole. We believe this is the second case report describing disseminated Acanthamoeba infection in a lung transplant recipient. We also describe successful outcome with a combination of lipid formulation of amphotericin B and voriconazole, drugs that have not been previously reported to treat Acanthamoeba.

Publication types

  • Case Reports

MeSH terms

  • Acanthamoeba*
  • Acute Disease
  • Amebiasis / drug therapy*
  • Amebiasis / etiology*
  • Amphotericin B / administration & dosage*
  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Chemistry, Pharmaceutical
  • Female
  • Humans
  • Injections, Intravenous
  • Lipids / administration & dosage
  • Lung Transplantation / adverse effects*
  • Middle Aged
  • Postoperative Complications / therapy*
  • Pyrimidines / administration & dosage*
  • Skin Diseases, Parasitic / etiology*
  • Skin Diseases, Parasitic / therapy*
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Voriconazole

Substances

  • Antiprotozoal Agents
  • Lipids
  • Pyrimidines
  • Triazoles
  • Amphotericin B
  • Voriconazole